MaxCyte, Inc. (MXCT)
Health Care · Cell therapy and cell engineering platform technology · Nasdaq
MaxCyte enables cell therapy development through proprietary electroporation technology that delivers molecules into cells for engineering next-generation cell-based medicines.
What MaxCyte, Inc. does
MaxCyte is a commercial cell engineering company that develops and commercializes Flow Electroporation technology platforms for biopharmaceutical companies and research institutions to engineer cells for cell therapies, gene therapies, and cell-based research. The company offers its ExPERT platform family comprising multiple electroporation instruments (DTx, ATx, STx, GTx, VLx) and proprietary disposables and consumables. MaxCyte also recently acquired SeQure Dx to provide gene-editing assessment services across R&D through commercialization.
Themes: ["Cell therapy / cell engineering"]
Fundamentals
- Price$1.33 as of 2026-07-10 close
- Market cap$142M as of 2026-07-13
- 1-year return-41.7% as of 2026-07-10 close
- Net margin-121.2% as of 2026-07-13
- Gross margin+80.5% as of 2026-07-13
- ROE-22.0% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Revenue growth (YoY)-14.3% as of 2026-07-13
- Revenue CAGR (3y)-9.3% SEC XBRL
- Beta1.48 as of 2026-07-13
Key risks (from latest filing)
["Company is unprofitable with negative revenue growth of -14.3% YoY and net margin of -121.16%, burning cash to fund operations"]
Competitors & peers
- Lonza (cell and gene therapy manufacturing/services)
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.